Philadelphia Chromosome & BCR-ABL

📋 Key Information Summary

📋

The Philadelphia chromosome results from the balanced reciprocal translocation t(9;22)(q34;q11), creating the BCR-ABL1 fusion oncogene on the derivative chromosome 22 — the hallmark of chronic myeloid leukaemia (CML) and present in approximately 20–30% of adult and 2–5% of paediatric acute lymphoblastic leukaemia (ALL).
The BCR-ABL1 fusion protein is a constitutively active tyrosine kinase that drives uncontrolled proliferation, reduces apoptosis, and perturbs adhesion molecule signalling in haematopoietic stem cells.
Fusion transcript size determines disease biology: p210 BCR-ABL (e13a2 or e14a2) is typical of CML; p190 (e1a2) predominates in Ph+ ALL; p230 (e19a2) is associated with chronic neutrophilic leukaemia.
Detection requires complementary methods: conventional cytogenetics (karyotyping) detects the translocation; fluorescence in situ hybridisation (FISH) confirms BCR-ABL1 rearrangement; real-time quantitative PCR (RQ-PCR) is the gold standard for monitoring molecular response and minimal residual disease.
Tyrosine kinase inhibitors (TKIs) targeting the ABL1 kinase domain have transformed CML from a fatal disease to one with near-normal life expectancy — imatinib (Glivec®) is PBS-listed as the first-line agent.
Second-generation TKIs — dasatinib (Sprycel®), nilotinib (Tasigna®) — are PBS-authority options for imatinib-resistant or intolerant CML; ponatinib (Iclusig®) is available for T315I-mutated disease.
In Ph+ ALL, TKI therapy (dasatinib preferred) combined with intensive chemotherapy or corticosteroid-only regimens significantly improves complete remission rates and overall survival.
Molecular monitoring by RQ-PCR every 3 months is mandatory in CML; achievement of major molecular response (MMR, BCR-ABL1 IS ≤0.1%) at 12 months is associated with excellent long-term outcomes.
Resistance mechanisms include BCR-ABL1 kinase domain mutations (T315I the most refractory), BCR-ABL1 amplification, and clonal evolution; mutation analysis is essential when treatment milestones are not met.
Treatment-free remission (TFR) is achievable in ~40–60% of patients with sustained deep molecular response (DMR, MR4 or better for ≥2 years) — TKI cessation must occur within a structured molecular monitoring programme.
Aboriginal and Torres Strait Islander peoples may experience diagnostic delay and reduced access to molecular monitoring; engagement with local haematology services and culturally safe care pathways is essential.
All TKI therapy must be managed by or in consultation with a haematologist; molecular response milestones are defined by the European LeukemiaNet (ELN) 2020 recommendations.

Introduction & Australian Epidemiology

The Philadelphia (Ph) chromosome — first described by Nowell and Hungerford in 1960 — is the product of a balanced reciprocal translocation between chromosomes 9 and 22, designated t(9;22)(q34;q11). This rearrangement fuses the ABL1 proto-oncogene (from 9q34) with the BCR gene (from 22q11), generating the BCR-ABL1 fusion oncogene on the derivative chromosome 22. The resulting fusion protein is a constitutively active tyrosine kinase that drives uncontrolled haematopoietic cell proliferation and is the central molecular lesion in chronic myeloid leukaemia (CML) and a proportion of acute lymphoblastic leukaemia (ALL).

The discovery of the Ph chromosome as the first consistent chromosomal abnormality in human cancer, and the subsequent development of targeted tyrosine kinase inhibitors (TKIs), represents one of the greatest successes of molecular oncology. Imatinib mesylate, introduced in clinical trials in the late 1990s, transformed CML from a disease with a median survival of 3–5 years to one in which most patients can expect a near-normal lifespan.

Parameter	Value
Australian CML incidence	~350–400 new cases per year (age-standardised rate ~1.6 per 100,000)
Median age at CML diagnosis	~55–60 years; bimodal with a second peak in the 70s
Ph+ ALL proportion	~20–30% of adult ALL; 2–5% of paediatric ALL
5-year overall survival (CML, chronic phase, TKI era)	>90% in Australia
Aboriginal & Torres Strait Islander representation	Limited data; AIHW reports suggest later presentation and lower survival for haematological malignancies

Understanding the molecular biology of the Ph chromosome and BCR-ABL1 is fundamental to rational use of TKIs, interpretation of molecular monitoring, and management of resistance. This guideline provides a comprehensive overview of the translocation, the molecular target, detection methodologies, and clinical significance with emphasis on the Australian therapeutic landscape.

Translocation & Molecular Biology

The t(9;22)(q34;q11) Rearrangement

The Philadelphia chromosome arises from a balanced reciprocal translocation between the long arms of chromosomes 9 and 22. During this rearrangement, the ABL1 gene (Abelson murine leukaemia viral oncogene homolog 1) is excised from its normal position at 9q34 and translocated to the breakpoint cluster region (BCR) gene at 22q11. The reciprocal translocation places a portion of BCR on the derivative chromosome 9, though the pathogenic fusion resides on the derivative chromosome 22 (the Ph chromosome).

BCR Gene Structure & Breakpoint Regions

The BCR gene spans approximately 135 kb and contains 23 exons. The breakpoint in BCR occurs within the major breakpoint cluster region (M-bcr), a 5.8 kb area spanning exons 12–16. Three principal breakpoint zones are recognised:

M-bcr (major): Breakpoint between exons 13 and 14 (b2) or 14 and 15 (b3) — produces e13a2 (b2a2) or e14a2 (b3a2) transcripts encoding the p210 fusion protein. Found in ~95% of CML and ~60% of adult Ph+ ALL.
m-bcr (minor): Breakpoint between exons 1 and 2 (e1) — produces e1a2 transcript encoding the p190 fusion protein. Predominant in ~60–80% of Ph+ ALL and a rare variant of CML.
μ-bcr (micro): Breakpoint between exons 19 and 20 (e19) — produces e19a2 transcript encoding the p230 fusion protein. Associated with chronic neutrophilic leukaemia.

ABL1 Gene Structure

The ABL1 gene on chromosome 9 spans approximately 230 kb and contains 11 exons. The breakpoint in ABL1 is variable, occurring anywhere upstream of exon 2 (a2). All resulting BCR-ABL1 fusion transcripts retain exons 2–11 of ABL1, which encode the tyrosine kinase domain. The breakpoint variation in ABL1 does not significantly alter the fusion protein function.

Clonal Evolution & Additional Cytogenetic Abnormalities

CML in chronic phase typically shows the sole Ph chromosome abnormality. Disease progression is accompanied by clonal evolution — acquisition of additional cytogenetic abnormalities including trisomy 8, isochromosome 17q, double Ph chromosome, and trisomy 19. These secondary abnormalities correlate with accelerated phase and blast crisis, and may herald TKI resistance.

⚠️

Clinical significance: The e1a2 (p190) transcript, while more common in Ph+ ALL, may also be detected in CML — often in association with monocytosis. Its presence in CML may confer a more aggressive course and requires differentiation from co-occurring Ph-negative clones. Always confirm transcript type at diagnosis.

BCR-ABL Tyrosine Kinase Activity

Constitutive Kinase Activation

The BCR-ABL1 fusion protein retains the SH1 (kinase), SH2, and SH3 domains of ABL1, but the N-terminal BCR sequences replace the auto-inhibitory cap of native ABL1. The BCR coiled-coil oligomerisation domain promotes tetramerisation of BCR-ABL1, leading to trans-autophosphorylation and constitutive activation of the kinase domain. This results in ligand-independent phosphorylation of downstream substrates.

Downstream Signalling Pathways

Constitutively active BCR-ABL1 activates multiple oncogenic signalling cascades simultaneously:

RAS/MAPK pathway: Drives cellular proliferation via GRB2-SOS-RAS-RAF-MEK-ERK signalling.
PI3K/AKT/mTOR pathway: Promotes cell survival and inhibits apoptosis via phosphorylation of BAD, caspase-9, and FOXO transcription factors.
JAK/STAT pathway: STAT5 phosphorylation is a major mediator of BCR-ABL1 transforming activity — drives expression of anti-apoptotic genes (BCL-XL) and cell cycle regulators.
MYC activation: Transcriptional upregulation of MYC drives proliferation and stem cell self-renewal.
CrkL phosphorylation: CrkL is a direct substrate of BCR-ABL1 and a surrogate marker of kinase activity; used in ex vivo drug sensitivity assays.

Impact on Haematopoietic Stem Cells

BCR-ABL1 confers several functional changes to the leukaemic stem cell:

Reduced adhesion: Downregulation of integrins and cadherins disrupts normal stem cell–stroma interactions, releasing progenitors into the circulation.
Increased proliferation: Shortened cell cycle duration in the progenitor compartment.
Resistance to apoptosis: BCL-XL upregulation and p53 inactivation protect against programmed cell death.
Genomic instability: Impaired DNA repair via altered DNA-PKcs function and reactive oxygen species generation promotes acquisition of secondary mutations.

The ABL1 Kinase Domain — TKI Binding

The ATP-binding pocket of the ABL1 kinase domain is the pharmacological target of all approved TKIs. The kinase domain exists in two conformations:

Active (DFG-in) conformation: The activation loop adopts an open position, exposing the ATP-binding site. Imatinib binds preferentially to the inactive conformation.
Inactive (DFG-out) conformation: The activation loop folds over the catalytic site. Imatinib, nilotinib, and ponatinib bind to this conformation.

Dasatinib binds to both active and inactive conformations, which partly explains its potency against some imatinib-resistant mutants (except T315I). The T315I "gatekeeper" mutation directly disrupts a critical hydrogen bond between imatinib and the kinase domain, conferring resistance to all first- and second-generation TKIs; only ponatinib and asciminib retain activity against this mutation.

💊

Imatinib

Glivec® · Novartis · ABL1/BCR-ABL1 TKI

Adult dose (CML-CP) 400 mg PO once daily with food

Adult dose (CML-AP/BP) 600–800 mg PO daily (divided BID for 800 mg)

Paediatric dose 260 mg/m²/day PO (max 400 mg); BSA-based dosing

Renal adjustment eGFR 20–40: reduce dose by 50%; eGFR <20: max 100 mg/day; avoid in dialysis

Hepatic adjustment Mild (Child-Pugh A): reduce by 25%; Moderate–Severe (Child-Pugh B/C): avoid

PBS status ✔ PBS General Benefit (CML, Ph+ ALL)

💊

Dasatinib

Sprycel® · Bristol-Myers Squibb · 2nd-gen TKI

Adult dose (CML-CP) 100 mg PO once daily (with or without food)

Adult dose (Ph+ ALL) 140 mg PO once daily

Paediatric dose 60 mg/m²/day PO (max 100 mg) for Ph+ ALL

Renal adjustment No dose reduction required; caution in severe impairment

Hepatic adjustment Mild–moderate: reduce by 25–50%; Severe: avoid

PBS status ⚡ PBS Authority Required (2nd-line CML; Ph+ ALL)

💊

Nilotinib

Tasigna® · Novartis · 2nd-gen TKI

Adult dose (CML-CP, 2nd-line) 400 mg PO BID (12-hourly, fasting — no food for 2 h before/1 h after)

Paediatric dose 230 mg/m² BID (max 400 mg BID); BSA-based

Renal adjustment Caution in severe impairment; no specific dose reduction defined

Hepatic adjustment Mild (Child-Pugh A): no change; Moderate–Severe: avoid

PBS status ⚡ PBS Authority Required (2nd-line CML)

💊

Ponatinib

Iclusig® · Incyte · 3rd-gen TKI (pan-BCR-ABL1)

Adult dose 45 mg PO once daily; reduce to 30 mg then 15 mg for response or toxicity

Key indication T315I mutation; resistant/intolerant to ≥2 prior TKIs

Renal adjustment eGFR <30: not recommended

Hepatic adjustment Child-Pugh B: 30 mg daily; Child-Pugh C: avoid

PBS status 🔴 PBS Authority Required — Specialist (T315I or failure of ≥2 TKIs)

🚨

Cardiovascular risk: Nilotinib and ponatinib carry significant cardiovascular and thrombotic risks. Nilotinib requires baseline ECG (correct QTc <450 ms), fasting administration, and regular cardiovascular risk assessment. Ponatinib mandates baseline cardiac assessment, aggressive risk factor modification, and dose reduction strategies. Refer to PBS authority criteria and product information before prescribing.

Detection Methods (FISH, PCR)

Accurate detection and quantification of the Philadelphia chromosome and BCR-ABL1 fusion is essential at diagnosis (for treatment selection) and throughout therapy (for molecular monitoring). Three complementary laboratory methods are employed, each with distinct capabilities and limitations.

Conventional Cytogenetics (G-Banded Karyotyping)

Metaphase cytogenetic analysis of bone marrow aspirate remains the standard method for initial detection of t(9;22)(q34;q11). Twenty or more metaphases should be analysed. The Ph chromosome appears as a shortened chromosome 22. Karyotyping also identifies additional cytogenetic abnormalities (clonal evolution) that define accelerated phase.

Sensitivity: ~5% (1 in 20 metaphases) — cannot detect submicroscopic rearrangements.
Turnaround: 10–21 days (requires viable dividing cells).
Limitations: Requires bone marrow aspirate; cannot detect cryptic insertions; inadequate if metaphases are insufficient (<20 analysed).
Availability: All major Australian haematology centres (Royal Adelaide, Westmead, Peter MacCallum, PathWest, Sullivan Nicolaides).

Fluorescence In Situ Hybridisation (FISH)

Interphase FISH uses fluorescently labelled DNA probes flanking the BCR and ABL1 breakpoint regions. In the absence of rearrangement, separate red (ABL1) and green (BCR) signals are seen; the Ph translocation produces a fusion (yellow/orange) signal. Dual-fusion (D-FISH) and extra-signal (ES-FISH) probe strategies are available.

Sensitivity: ~1–5% on interphase nuclei (analyses 200–500 cells).
Turnaround: 2–5 days.
Applications: Confirming BCR-ABL1 when cytogenetics fails or is inadequate; monitoring when PCR is unavailable; detecting variant translocations (complex three-way rearrangements).
Limitations: Cannot distinguish transcript type (p210 vs p190); false negatives in CML with cryptic insertions; lower sensitivity than PCR for monitoring.
MBS consideration: Investigated under MBS item 73307 (in situ hybridisation, per probe); bone marrow FISH typically billed with MBS item 73313.

Real-Time Quantitative PCR (RQ-PCR)

RQ-PCR (also called RT-qPCR) is the gold standard for molecular monitoring of CML and Ph+ ALL. It quantifies BCR-ABL1 mRNA transcript levels from peripheral blood (or bone marrow), expressed on the International Scale (IS) as BCR-ABL1^IS percentage. This method is used for:

Baseline quantification: Establishes the initial BCR-ABL1 level at diagnosis.
Treatment monitoring: Molecular response milestones guide TKI therapy decisions per ELN 2020 criteria.
Deep molecular response assessment: Detection of MR4 (BCR-ABL1^IS ≤0.01%) and MR4.5 (≤0.0032%) — essential for TFR eligibility.
Relapse detection: Rising BCR-ABL1 levels indicate loss of response before haematological relapse.

Milestone	BCR-ABL1^IS	Log Reduction	Clinical Significance
Complete cytogenetic response (CCyR)	≤1%	≥2 log	Associated with progression-free survival >95%
Major molecular response (MMR)	≤0.1%	≥3 log	Key treatment milestone at 12 months; optimal response
MR4	≤0.01%	≥4 log	Deep molecular response; TFR eligibility threshold
MR4.5	≤0.0032%	≥4.5 log	Sustained MR4.5 for ≥2 years preferred for TFR

Molecular Monitoring Frequency — ELN 2020 Australian Application

Diagnosis

RQ-PCR + cytogenetics + mutation screen baseline; confirm transcript type (e13a2/e14a2 vs e1a2)

Every 3 months (years 1–3)

RQ-PCR on peripheral blood; assess molecular milestones at 3, 6, 12 months

Every 3–6 months (year 3+)

RQ-PCR if stable MMR or better; increase to 3-monthly if any concern

If TFR attempt

Monthly RQ-PCR for 6 months, then every 2–3 months for ≥5 years; resume TKI if loss of MMR

⚠️

IS calibration: All Australian laboratories performing RQ-PCR for CML monitoring must report results on the International Scale (IS). Laboratories without IS alignment must use a laboratory-specific conversion factor (LS-CF). Ensure your laboratory participates in an external quality assurance (EQA) programme such as the Australasian Leukaemia & Lymphoma Group (ALLG) molecular monitoring programme or the European BIOMED-1 EQA scheme.

BCR-ABL1 Kinase Domain Mutation Analysis

Direct sequencing (Sanger or next-generation sequencing) of the ABL1 kinase domain is indicated when:

Warning or failure milestones are reached on ELN 2020 criteria.
Rising BCR-ABL1 levels (≥2 log increase from best response) confirmed on repeat testing.
Loss of previously achieved MMR.
Disease progression (accelerated phase or blast crisis).

Over 100 kinase domain mutations have been described; clinically important mutations include T315I (gatekeeper — resistant to imatinib, dasatinib, nilotinib), E255K/V, Y253H, F317L, and V299L. Mutation-specific TKI selection is guided by sensitivity profiles:

Mutation	Imatinib	Dasatinib	Nilotinib	Ponatinib
T315I	Resistant	Resistant	Resistant	Sensitive
Y253H	Resistant	Sensitive	Resistant	Sensitive
E255K/V	Resistant	Sensitive	Resistant	Sensitive
F317L	Sensitive	Resistant	Sensitive	Sensitive
V299L	Sensitive	Resistant	Sensitive	Sensitive
E255K/V	Resistant	Variable	Resistant	Sensitive

Mutation analysis is available at major Australian molecular haematology laboratories (e.g., Royal Melbourne Hospital, SA Pathology, Pathology Queensland). Turnaround is typically 2–4 weeks. NGS-based panels can detect low-level mutant clones (<15%) not identified by Sanger sequencing.

Clinical Significance & TKI Targeting

Ph Chromosome in Chronic Myeloid Leukaemia

The Ph chromosome is present in >95% of CML cases at diagnosis and is a defining WHO criterion for the disease. CML follows a triphasic natural history — chronic phase (CP), accelerated phase (AP), and blast crisis (BC) — with TKI therapy dramatically altering the trajectory. The landmark IRIS trial (imatinib vs interferon + cytarabine) demonstrated 8-year CCyR rates of 83% and 8-year overall survival of 85% with imatinib in CP-CML.

Ph Chromosome in Acute Lymphoblastic Leukaemia

Ph+ ALL is characterised by the presence of t(9;22) and/or BCR-ABL1 fusion. It is the most common subtype of ALL in adults (20–30%) but is rare in children (2–5%). The fusion transcript in Ph+ ALL is frequently p190 (e1a2). Ph+ ALL is historically associated with a poor prognosis, but the addition of TKIs to chemotherapy has significantly improved outcomes.

Optimal

ELN 2020 Optimal Response

BCR-ABL1^IS ≤10% at 3 months; ≤1% at 6 months; ≤0.1% (MMR) at 12 months

Continue current TKI; monitor Q3 months

Warning

ELN 2020 Warning

BCR-ABL1^IS >10% at 3 months; >1% at 6 months; >0.1% at 12 months; any rise during treatment; low-level kinase domain mutation

Consider TKI switch; increase monitoring; mutation analysis

Failure

ELN 2020 Failure

No CHR at 3 months; no CyR at 6 months; loss of CHR, CCyR, or MMR; high-level mutation (T315I); clonal evolution; progression to AP/BC

Switch TKI immediately; mutation analysis mandatory; consider allogeneic HSCT

TKI Therapy Algorithm in CML — Australian Practice

1

First-Line — Chronic Phase

Imatinib 400 mg daily (PBS General Benefit). Second-generation TKI (nilotinib 300 mg BID or dasatinib 100 mg OD) may be considered first-line in high-risk Sokal/ELTS score, but PBS Authority criteria require documented imatinib failure/intolerance for subsidised second-line use.

2

Second-Line — Imatinib Failure or Intolerance

Switch to dasatinib or nilotinib (PBS Authority Required). Choice guided by comorbidities (pleural effusion risk → avoid dasatinib; cardiovascular risk → avoid nilotinib) and mutation profile if available.

3

Third-Line or T315I Mutation

Ponatinib 45 mg daily (PBS Authority — Specialist; T315I or failure of ≥2 TKIs). Dose reduction to 30 mg or 15 mg once response achieved or for toxicity. Asciminib (Scemblix®) is a STAMP inhibitor approved by the TGA and emerging as a PBS option for refractory CML — check current PBS schedule.

4

Advanced Phase (AP/BC)

TKI at higher dose (imatinib 600–800 mg or dasatinib 140 mg) + intensive chemotherapy. Proceed to allogeneic haematopoietic stem cell transplant (HSCT) when in chronic phase remission if eligible. Lymphoid blast crisis treated with ALL-type induction + TKI.

TKI Therapy in Ph+ ALL

The standard of care for Ph+ ALL in Australia is a combination of TKI with either intensive chemotherapy or corticosteroid-only protocols (especially in older adults):

Younger adults (<65 years): Dasatinib 140 mg daily + intensive chemotherapy (e.g., HyperCVAD or the GRAALL-2014 protocol). Dasatinib is preferred over imatinib in ALL due to superior CNS penetration and potency.
Older adults (≥65 years): Dasatinib + corticosteroid induction (± vincristine) — based on the EWALL-Ph-01 study showing high CR rates with reduced toxicity.
Paediatric Ph+ ALL: Dasatinib 60 mg/m²/day integrated into high-risk ALL chemotherapy backbone (COG/ALLTogether protocols). Allogeneic HSCT in first CR is recommended for high-risk patients or those with persistent MRD.
Blinatumomab + TKI: Emerging data (ECOG-ACRIN E1910) suggest blinatumomab (Blincyto®) + TKI may replace chemotherapy in Ph+ ALL — check local ALLG trial availability.

Treatment-Free Remission (TFR)

TFR — discontinuation of TKI with sustained undetectable molecular residual disease — is achievable in ~40–60% of CML patients who achieve durable deep molecular response. Australian eligibility criteria (aligned with ELN 2020 and NCCN):

CML in chronic phase only.
TKI therapy for ≥5 years total (≥3 years on first-line TKI; ≥2 years on second-line TKI).
Confirmed MR4 (BCR-ABL1^IS ≤0.01%) for ≥2 years prior to cessation.
Access to validated IS-standardised RQ-PCR with sensitivity of MR4.5.
Structured molecular monitoring programme: monthly PCR for 6 months, then 2–3 monthly for ≥5 years.
No prior AP/BC; no kinase domain mutations.

✅

TFR management: If BCR-ABL1^IS rises above 0.1% (loss of MMR) during TKI-free phase, the TKI must be re-introduced immediately. Outcome after re-treatment is excellent — >95% regain MMR. TFR should only be attempted under specialist supervision with validated molecular monitoring.

Allogeneic Haematopoietic Stem Cell Transplant (HSCT)

While TKI therapy is first-line for CML, allogeneic HSCT retains a role in:

CML in accelerated phase or blast crisis (after TKI + chemotherapy to second chronic phase).
TKI-refractory CML with no remaining TKI options (especially T315I prior to ponatinib availability or ponatinib failure).
Ph+ ALL in first complete remission — especially adults with high-risk features, persistent MRD, or not in MMR at end of consolidation.
Paediatric Ph+ ALL — HSCT in CR1 recommended for those with persistent MRD or high-risk genetics.

Australian transplant centres performing HSCT for CML/Ph+ ALL include Royal Adelaide Hospital, Westmead Hospital, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and Royal Brisbane and Women's Hospital. Donor registries include the Australian Bone Marrow Donor Registry (ABMDR) and international cord blood banks.

Special Populations

🤰

Pregnancy

All TKIs are Category D (teratogenic)

Imatinib, dasatinib, nilotinib, and ponatinib are all teratogenic in animal studies and must be discontinued before conception or immediately upon confirmed pregnancy. Interferon-α is the preferred non-teratogenic option for managing CML during pregnancy. Leukapheresis may be required for symptomatic hyperleucocytosis. Breastfeeding is contraindicated during TKI therapy.

👶

Paediatrics

Imatinib paediatric dose: 260 mg/m²/day PO (max 400 mg)

Imatinib is PBS-listed for paediatric CML. Growth retardation is a recognised adverse effect — monitor height velocity and consider endocrine referral. Paediatric CML is rare (~2% of all childhood leukaemias); consider referral to a paediatric haematology centre (e.g., Children's Hospital at Westmead, Royal Children's Hospital Melbourne).

Ph+ ALL — Dasatinib 60 mg/m²/day PO (max 100 mg)

Dasatinib is PBS-listed for paediatric Ph+ ALL. Integrated into standard-risk or high-risk ALL backbone depending on MRD response.

🧓

Elderly (≥70 years)

Imatinib preferred first-line

Favourable safety profile in elderly; dose reduction to 300 mg may be considered for toxicity. Nilotinib and ponatinib carry higher cardiovascular risk in older patients. Ph+ ALL in elderly: dasatinib + corticosteroids (EWALL protocol) is preferred over intensive chemotherapy.

🫘

Renal Impairment

Imatinib: dose reduce by 50% if eGFR 20–40; max 100 mg if eGFR <20

Imatinib is partly renally cleared. Dasatinib has minimal renal excretion — preferred in severe CKD. Monitor for fluid retention with all TKIs in renal impairment. No dose adjustment needed for nilotinib in mild-moderate CKD.

🫁

Hepatic Impairment

All TKIs hepatically metabolised — dose reduction or avoidance required

Imatinib: reduce by 25% in mild hepatic impairment; avoid in moderate-severe. Dasatinib: avoid in severe impairment. Nilotinib: avoid in moderate-severe. Ponatinib: 30 mg in Child-Pugh B; avoid in Child-Pugh C. Monitor LFTs at baseline and monthly during therapy.

🛡️

Immunocompromised

TKIs may cause lymphopenia

Dasatinib may cause large granular lymphocyte expansion (associated with better response) or significant pleural effusion with immunosuppression. All TKIs may reactivate hepatitis B — screen HBsAg and anti-HBc before commencing therapy. Prophylactic antiviral therapy (e.g., entecavir) is recommended for HBsAg-positive patients.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Diagnostic delay

Aboriginal and Torres Strait Islander peoples may present later in disease course due to reduced access to primary care and pathology services in remote and regional areas. Later presentation increases risk of accelerated phase or blast crisis at diagnosis. Active case-finding through routine FBC and blood film review in communities with access to GP services is recommended.

Molecular monitoring access

RQ-PCR monitoring for CML requires specimen transport to centralised laboratories (typically in capital cities). Patients in remote communities face logistical challenges — extended transport times may affect RNA integrity. Telehealth consultations with specialist haematologists (funded under MBS) and coordination with local Aboriginal Medical Services (AMS) for blood collection can improve monitoring compliance.

PBS and medication access

Imatinib and other TKIs are PBS-subsidised but require ongoing supply chain access. Closing the PBS co-payment gap for Aboriginal and Torres Strait Islander patients (through the PBS Co-payment measure) ensures free or reduced-cost medications. Remote area pharmacies may have limited TKI stock — early dispensing and medication planning is essential.

Cultural safety

Engagement with Aboriginal Health Workers and cultural liaison officers is critical for treatment adherence and informed consent. Explanation of complex molecular concepts (e.g., MRD, TFR) should be provided in culturally appropriate language. Yarning-based approaches to chronic disease education may improve understanding and shared decision-making.

Comorbidity burden

Higher prevalence of cardiovascular disease, renal disease, and diabetes in Aboriginal and Torres Strait Islander populations affects TKI selection. Nilotinib and ponatinib should be used with particular caution given cardiovascular risk profiles. Imatinib has a more favourable cardiovascular safety profile and remains the preferred first-line agent.

Data and research gaps

There is a significant gap in Australian data regarding CML incidence, molecular characteristics, TKI response rates, and survival in Aboriginal and Torres Strait Islander peoples. The AIHW Cancer Data and Aboriginal and Torres Strait Islander people reports highlight under-reporting and poorer haematological cancer outcomes. Research participation and registry linkage should be encouraged with community consent.

📚 References

1. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.
3. Hughes TP, Saglio G, Quintás-Cardama A, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015;29(9):1832–1838.
4. Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10–20.
5. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312. [Note: cross-referenced for methodology context]
6. Australian Institute of Health and Welfare (AIHW). Cancer in Aboriginal & Torres Strait Islander people of Australia. AIHW Cat. No. CAN 113. Canberra: AIHW; 2018.
7. Rousselot P, Johnson-Ansah M, Huguet F, et al. Personalized daily doses of dasatinib in chronic phase chronic myeloid leukemia: a feasibility study. Haematologica. 2015;100(1):e10–e12.
8. Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–3719.
9. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035.
10. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias. N Engl J Med. 2013;369(19):1783–1796.
11. Pharmaceutical Benefits Scheme (PBS). Imatinib, dasatinib, nilotinib, ponatinib — Schedule listings. Australian Government Department of Health. Available at: https://www.pbs.gov.au
12. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent assessment of responses in patients with chronic myeloid leukemia. Leukemia. 2007;21(10):2083–2090.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated). [For ATSI research considerations]
14. Cancer Council Australia. Clinical practice guidelines for the management of chronic myeloid leukaemia. Available at: https://www.cancer.org.au